bromocriptine

(redirected from Bromocriptine mesylate)
Also found in: Dictionary, Medical.
Related to Bromocriptine mesylate: hyperprolactinemia, Cabergoline

bromocriptine

[‚brō·mō′krip‚tēn]
(organic chemistry)
C32H40BrN5O5 A polypeptide alkaloid that is a derivative of the ergotoxin group of ergot alkaloids and is a dopamine receptor agonist.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
[7] In a randomized provocative study by Schwartz, insulin-treated T2DM patients were given high-dose bromocriptine mesylate for 12 weeks.
They received daily add-on bromocriptine mesylate for 52 weeks, and the analysis was performed using intent to treat modified and evaluable per protocol basis.
Effect of bromocriptine mesylate in 22 obese T2DM subjects was studied in a double-blinded trial lasting 16 weeks.
Bromocriptine mesylate monotherapy significantly reduced HbA1c from 8.7% to 8.1% and fasting blood glucose levels compared to placebo.
in 1999 conducted 24-week randomized trials of quick release preparation of bromocriptine mesylate in type 2 diabetic patients in a double-blind fashion.
(c) Dopamine receptor agonists like bromocriptine mesylate and dantrolene (a muscle relaxant) can be used when attempting to reintroduce anti-psychotic medications, a process that should be closely monitored.
[4] Bromocriptine mesylate is one such drug that upregulates hypothalamic dopaminergic tone reducing insulin resistance and improving glucose tolerance.
To study the efficacy of bromocriptine mesylate as an add-on therapy in patients with T2DM inadequately controlled on two oral antidiabetic drugs.
Bromocriptine mesylate was started as one tablet (0.8 mg) orally daily at 8 am with food and increased by one tablet per week until a maximum recommended daily dose of six tablets (4.8 mg/day) or until the maximum tolerated dose was achieved.
Efficacy of bromocriptine mesylate was assessed by measuring FBS (mg/dL), PPBS (mg/dL) and HbA1c (%) at 0, 6 and 12 weeks.
All 50 patients were continued on bromocriptine mesylate add-on therapy until 12 weeks with further significant reduction in all three parameters (P < 0.05).